News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Inamco International Corporation Re-Announces The Completions Of Multi-Million Dollar Acquisitions



10/19/2005 5:10:50 PM

SOUTH PLAINFIELD, N.J., April 7 /PRNewswire-FirstCall/ -- Inamco International Corp., IICC, is re-announcing that it completed the acquisitions of two separate companies in October of 2003. As previously announced, one company is a manufacturer of generic pharmaceuticals and the other company is a manufacturer of in-vitro diagnostic test kits.

"The reason for the re-announcement of these acquisitions," states Mr. Varges George, the President and CEO of Inamco, "is because Inamco has gone through a 'self-imposed' quiet period. For the past 5 1/2 months, Inamco has been complying with rules, regulations, and procedures that require us to perform a full 3rd party external financial audit on Inamco and its wholly owned subsidiaries, Medicos Laboratories, Inc., and Advanced Diagnostics, Inc."

Mr. George continues to state that, "We are extremely pleased that all of our hard work is coming to fruition. As we finish our financial audit, we will continue to prepare for substantial growth as we implement our business practices to increase both revenue and shareholder equity. We will continue to inform the public as we make new strides."

Medicos Laboratories, Inc. is FDA registered, and operates primarily as a research and development manufacturing company of both prescription and non-prescription generic pharmaceuticals. Among the products presently being manufactured by Medicos, include: Acetaminophen tablets, Milk of Magnesia chewable tablets, Guaifenesin/Dextromethorphan 1200/60 SR tablets, and Guaifenesin/Dextromethorphan 1000/60 SR tablets.

Advanced Diagnostics, Inc. is also an FDA registered company which is fully compliant with current Good Manufacturing Practices (cGMP) for the manufacture and packing of a diverse range of diagnostic products in the field of Immunology, Clinical Chemistry, Drugs of Abuse, Elisa Tests, and Rapid One Step Tests. These diagnostic products are presently being marketed through a network of distributors in several countries worldwide, and amongst its more prominent clients are the International Red Cross, the World Health Organization and the Center for Disease Control in Atlanta.

This press release includes statements that could be construed as "forward-looking" in nature. For such statements, Inamco claims the protection of the Private Securities Litigation Reform Act of 1995. Readers of this press release are cautioned, not to place undue reliance on these statements, which speak only as of the date on which they are made. These statements involve a number of risks and uncertainties, which include statements about Inamco's strategy and goals, and other statements that are not historical in fact. Individuals can review any material information provided by Inamco by accessing the Company's filings and annual reports submitted to the Securities and Exchange Commission, and such review should be evaluated with the understanding that actual results may differ materially from those stated or implied.

Inamco International Corp.

CONTACT: Mr. Varges George of Inamco International Corp.,+1-908-754-4880


Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES